Black Diamond Therapeutics, Inc.
NASDAQ:BDTXBiotechnology
-$0.04 today
- Market cap
- $82.18M
- Beta
- 3.23
- P/E (TTM)
- -2.2
- EPS (TTM)
- -$0.75
Volume 0.60M
Average 1.31M
BDTX EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Black Diamond Therapeutics, Inc.NASDAQ: BDTX
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA turns negative
Q1 FY2026 EBITDA was -$9.01M, compared with $56.63M a year earlier. Trailing-twelve-month EBITDA was -$38.09M.
Context
- EBITDA amounted to 32.4% of revenue in FY2025.
- EBITDA increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 5 analysts of -$41.97M (-284.9%) for the fiscal year ending Dec 2026, a slowdown from the +132.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$9.01M+11.6% QoQ
- Last fiscal yearDec 2025
- $22.69M+132.7% YoY
- LTMMar 2026
- -$38.09M-800.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -115.9% | — | — |
| 1 year | +132.7% | -284.9% | -417.7 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 22.69M USD
- Year-over-year change
- +132.7%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 22.69M | +132.7% |
| FY2024 | 2024-12-31 | (69.33M) | +15.5% |
| FY2023 | 2023-12-31 | (82.01M) | +9.5% |
| FY2022 | 2022-12-31 | (90.66M) | +27.7% |
| FY2021 | 2021-12-31 | (125.39M) | — |
EBITDA vs competitors
How BDTX compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -800.9% is the lowest of 11, against a peer median of +22.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $73.43M USD | +298.8% | — | 505.0% | |
| LTM Mar 2026 | -$6.67M USD | +35.5% | — | 13.1% | |
| LTM Mar 2026 | -$38.09M USD | -800.9% | — | — | |
| LTM Mar 2026 | -$46.56M USD | +46.6% | — | 67.3% | |
| LTM Mar 2026 | -$58.85M USD | +7.0% | — | — | |
| LTM Mar 2026 | -$69.83M USD | -147.0% | — | — | |
| LTM Mar 2026 | -$72.53M USD | +7.7% | — | 257.0% | |
| LTM Mar 2026 | -$75.47M USD | +22.0% | — | 33540.9% | |
| LTM Mar 2026 | -$84.35M USD | -214.9% | — | 142957.6% | |
| LTM Mar 2026 | -$111.97M USD | +23.4% | — | 999.5% | |
| FY2025 | -€128.15M EUR | +23.0% | — | 2858.6% | |
| Peer median (excluding BDTX) | — | +22.5% | — | 752.2% | |
Competitors are the stored peer set for BDTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 70M |
| Cost of Revenue | 0 | 0 | 437K | 0 | 325K |
| Gross Profit | 0 | 0 | (437K) | 0 | 69.68M |
| Gross Margin | — | — | — | — | 99.5% |
| Research & Development | 96.83M | 64.44M | 58.91M | 51.31M | 33.56M |
| Selling, General & Admin | 30.04M | 28.39M | 27.11M | 27.47M | 16.57M |
| Operating Expenses | 126.87M | 92.83M | 86.02M | 78.78M | 49.81M |
| Depreciation & Amortization | 205K | 508K | 437K | 343K | 325K |
| EBITDA | (125.39M) | (90.66M) | (82.01M) | (69.33M) | 22.69M |
| EBITDA Margin | — | — | — | — | 32.4% |
| Operating Income | (126.87M) | (92.83M) | (86.46M) | (78.78M) | 19.87M |
| Operating Margin | — | — | — | — | 28.4% |
| Interest Income | 3.46M | 2.03M | 1.92M | 2.18M | 4.06M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 1.28M | 1.66M | 4.02M | 9.11M | 2.5M |
| Income Before Tax | (125.6M) | (91.17M) | (82.44M) | (69.68M) | 22.37M |
| Pre-Tax Margin | — | — | — | — | 32.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (125.6M) | (91.17M) | (82.44M) | (69.68M) | 22.37M |
| Net Margin | — | — | — | — | 32.0% |
| EPS (Basic) | (3.47) | (2.52) | (1.88) | (1.27) | 0.39 |
| EPS (Diluted) | (3.47) | (2.52) | (1.88) | (1.27) | 0.39 |
| Weighted Avg Shares | 36.19M | 36.23M | 43.95M | 55.03M | 56.87M |
| Weighted Avg Shares (Diluted) | 36.19M | 36.23M | 43.95M | 55.03M | 57.56M |
Black Diamond Therapeutics, Inc.
NASDAQ:BDTX
Intrinsic Alpha fair value
Locked
Current Price
$1.43
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.